Roche drops out of Kosan development deal

After five years in partnership with Roche, Kosan Biosciences says it will seek a new partner for its experimental cancer therapy epothilone. Kosan is reacquiring all rights to KOS-1584, a therapy that has delivered signs of positive indications in an early-stage trial.

"Based on our discussions with Roche, we believe that the ending of our epothilone collaboration has been driven by a re-prioritization within Roche's research and development group rather than the value of our epothilone program," said Robert G. Johnson, Jr., Kosan's president and chief executive.

- here's the AP report for more information